Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MEM 3454: Phase IIa data

MEMY reported results from an 80-patient, double-blind, placebo-controlled, U.S. Phase IIa trial evaluating 5, 15 and 50 mg oral doses of MEM 3454 once daily for 8 weeks. MEMY

Read the full 296 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE